CN104244964A - 用于预防或治疗眼科病状的方法和组合物 - Google Patents

用于预防或治疗眼科病状的方法和组合物 Download PDF

Info

Publication number
CN104244964A
CN104244964A CN201380021305.4A CN201380021305A CN104244964A CN 104244964 A CN104244964 A CN 104244964A CN 201380021305 A CN201380021305 A CN 201380021305A CN 104244964 A CN104244964 A CN 104244964A
Authority
CN
China
Prior art keywords
phe
arg
lys
aromatic
dmt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380021305.4A
Other languages
English (en)
Chinese (zh)
Inventor
D·特拉维斯·威尔逊
K·乔治·穆尼
彼特·J·奥兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Peptides International Inc
Original Assignee
Stealth Peptides International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International Inc filed Critical Stealth Peptides International Inc
Priority to CN201510796422.9A priority Critical patent/CN105343869A/zh
Publication of CN104244964A publication Critical patent/CN104244964A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201380021305.4A 2012-02-22 2013-02-21 用于预防或治疗眼科病状的方法和组合物 Pending CN104244964A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510796422.9A CN105343869A (zh) 2012-02-22 2013-02-21 用于预防或治疗眼科病状的方法和组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261601878P 2012-02-22 2012-02-22
US61/601,878 2012-02-22
US201261605576P 2012-03-01 2012-03-01
US61/605,576 2012-03-01
PCT/US2013/027175 WO2013126597A1 (en) 2012-02-22 2013-02-21 Methods and compositions for preventing or treating ophthalmic conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510796422.9A Division CN105343869A (zh) 2012-02-22 2013-02-21 用于预防或治疗眼科病状的方法和组合物

Publications (1)

Publication Number Publication Date
CN104244964A true CN104244964A (zh) 2014-12-24

Family

ID=49006208

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380021305.4A Pending CN104244964A (zh) 2012-02-22 2013-02-21 用于预防或治疗眼科病状的方法和组合物
CN201510796422.9A Pending CN105343869A (zh) 2012-02-22 2013-02-21 用于预防或治疗眼科病状的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510796422.9A Pending CN105343869A (zh) 2012-02-22 2013-02-21 用于预防或治疗眼科病状的方法和组合物

Country Status (8)

Country Link
US (3) US20150018288A1 (enExample)
EP (4) EP3281634A1 (enExample)
JP (3) JP2015509500A (enExample)
CN (2) CN104244964A (enExample)
AU (3) AU2013222423A1 (enExample)
CA (1) CA2865317A1 (enExample)
HK (1) HK1204988A1 (enExample)
WO (1) WO2013126597A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109476700A (zh) * 2016-03-11 2019-03-15 隐形生物治疗公司 结晶盐形式
CN113710806A (zh) * 2019-02-08 2021-11-26 俄亥俄州创新基金会 用于眼部施用治疗剂的药物递送组合物以及其使用方法
CN113975402A (zh) * 2021-07-19 2022-01-28 河南大学 靶向脑缺血区线粒体的神经保护药物ss31-ha-qt及其荧光探针和应用
US11773136B2 (en) 2017-04-05 2023-10-03 Stealth Biotherapeutics Inc. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6518197B2 (ja) 2013-03-01 2019-05-22 ステルス バイオセラピューティックス コープ バース症候群の予防または治療のための方法及び組成物
CN116474071A (zh) * 2013-03-01 2023-07-25 康德生物医疗有限公司 治疗线粒体疾病的方法
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA2919992C (en) * 2013-08-01 2022-08-09 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
CN112457368A (zh) 2013-12-27 2021-03-09 康德生物医疗技术公司 药学相关的芳香族阳离子肽
WO2015103577A1 (en) * 2014-01-06 2015-07-09 Stealth Peptides International, Inc. Methods and compositions for preventing or treating dominant optic atrophy
US20170081363A1 (en) * 2014-03-03 2017-03-23 Stealth Biotherapeutics Corp Pharmaceutically relevant aromatic-cationic peptides
MX384877B (es) * 2014-03-03 2025-03-14 Novartis Ag Composiciones de éster de colina de ácido lipoico y métodos de uso.
JP6854771B2 (ja) 2015-03-06 2021-04-07 ステルス バイオセラピューティックス コープ 薬学的に適切なペプチドを調製するための方法
CA3020393A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
EP3771467A1 (en) * 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
KR102429281B1 (ko) * 2020-05-25 2022-08-05 (주)노바셀테크놀로지 신규 안구건조증 치료용 약학적 조성물
WO2023279067A1 (en) * 2021-07-01 2023-01-05 The Regents Of The University Of California Targeting piezo1 to treat inherited and age-related macular degenerations
KR20240108412A (ko) * 2021-10-20 2024-07-09 스텔스 바이오테라퓨틱스 인코포레이티드 안과 병태를 치료하거나, 예방하거나, 억제하거나, 경감하거나 발병을 지연시키기 위한 방법 및 펩타이드 모방체를 포함하는 조성물
CN115252555B (zh) * 2022-06-07 2023-11-21 西安电子科技大学 一种膜融合性脂质体、制备方法及其在蛋白质递送中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025734A1 (en) * 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US781405A (en) 1903-09-03 1905-01-31 Marcus A Coykendall Blank for dental plates.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2321560C (en) * 1998-03-13 2007-05-22 Johns Hopkins University School Of Medicine The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6217896B1 (en) 1999-04-01 2001-04-17 Uab Research Foundation Conjunctival inserts for topical delivery of medication or lubrication
CA2851972C (en) 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
AU2006292352B2 (en) * 2005-09-16 2012-02-09 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
CA2702984C (en) * 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
EP2252312B1 (en) * 2008-02-07 2014-04-09 Cornell University Methods for preventing or treating insulin resistance
US20100081707A1 (en) * 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
US8143219B2 (en) * 2008-02-26 2012-03-27 Cornell University Methods for prevention and treatment of acute renal injury
KR20120114282A (ko) * 2009-12-04 2012-10-16 유클리드 시스템스 코포레이션 황반변성, 당뇨망막병증 및 당뇨 황반부종의 예방 및 치료를 위한 조성물 및 방법
CN106620645A (zh) * 2010-07-09 2017-05-10 康德生物医疗技术公司 预防或治疗缺血/再灌注损伤之后无复流的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025734A1 (en) * 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109476700A (zh) * 2016-03-11 2019-03-15 隐形生物治疗公司 结晶盐形式
US11555053B2 (en) 2016-03-11 2023-01-17 Stealth Biotherapeutics Inc. Crystalline salt forms
US12252553B2 (en) 2016-03-11 2025-03-18 Stealth Biotherapeutics Inc. Crystalline salt forms
US11773136B2 (en) 2017-04-05 2023-10-03 Stealth Biotherapeutics Inc. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US12110345B2 (en) 2017-04-05 2024-10-08 Stealth Biotherapeutics Inc. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
CN113710806A (zh) * 2019-02-08 2021-11-26 俄亥俄州创新基金会 用于眼部施用治疗剂的药物递送组合物以及其使用方法
CN113975402A (zh) * 2021-07-19 2022-01-28 河南大学 靶向脑缺血区线粒体的神经保护药物ss31-ha-qt及其荧光探针和应用

Also Published As

Publication number Publication date
HK1204988A1 (en) 2015-12-11
EP3078384A1 (en) 2016-10-12
JP2019034947A (ja) 2019-03-07
US20180296630A1 (en) 2018-10-18
US20160361377A1 (en) 2016-12-15
CN105343869A (zh) 2016-02-24
EP3479839A1 (en) 2019-05-08
AU2019203713A1 (en) 2019-06-20
AU2017254849A1 (en) 2017-11-16
WO2013126597A1 (en) 2013-08-29
AU2013222423A1 (en) 2014-09-11
EP3281634A1 (en) 2018-02-14
US20150018288A1 (en) 2015-01-15
JP2015509500A (ja) 2015-03-30
CA2865317A1 (en) 2013-08-29
EP2817018A4 (en) 2015-09-23
JP2017214380A (ja) 2017-12-07
EP2817018A1 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
JP7642965B2 (ja) 眼疾患を予防または治療するための方法および組成物
US20180296630A1 (en) Methods and compositions for preventing or treating ophthalmic conditions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141224